PUBLISHER: Grand View Research | PRODUCT CODE: 1869707
PUBLISHER: Grand View Research | PRODUCT CODE: 1869707
The global biopharmaceutical cold chain third party logistics market size was estimated at USD 30.59 billion in 2024 and is projected to reach USD 74.46 billion by 2033, growing at a CAGR of 10.54% from 2025 to 2033. This market growth is due to the rising demand for temperature-sensitive pharmaceuticals, stringent drug storage and transportation regulatory requirements, and the global expansion of biologics and vaccine distribution.
In addition, increasing outsourcing of logistics services by pharmaceutical companies is further driving market expansion. Furthermore, increasing demand for biologics, vaccines, and temperature-sensitive drugs has significantly expanded the need for reliable cold chain logistics solutions. Biologics, including monoclonal antibodies, gene therapies, and recombinant proteins, require stringent temperature control, typically between 2°C and 8°C, with some requiring ultra-low storage at -70°C or lower-to maintain their efficacy.
Moreover, the growing trend towards personalized medicine has further boosted the need for specialized logistics solutions to ensure product integrity throughout the supply chain.
Global Biopharmaceutical Cold Chain Third Party Logistics Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global biopharmaceutical cold chain third party logistics market based on service, temperature range, and region: